Atlas Trials

Cardiff Oncology

7 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Cardiff Oncology

RecordFirmDate
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation (NCT06106308)Cardiff Oncology2024-02-27
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation (NCT05593328)Cardiff Oncology2023-03-17
Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma (NCT04752696)Cardiff Oncology2021-05-25
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation (NCT03829410)Cardiff Oncology2019-06-24
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03414034)Cardiff Oncology2018-08-14
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) (NCT03303339)Cardiff Oncology2017-11-17

Track Cardiff Oncology automatically

Every clearance here is in the API, with alerts when new ones post.